Many lipoxygenase and cytochrome P-450-mono-oxygenase inhibitors block endothelium-dependent vasodilatation by directly inhibiting EDRF action or guanylate cyclase rather than through their primary enzyme targets.
No takes yet. Share an insight, caveat, or question.
These inhibitors may confound vascular studies via off-target EDRF/guanylate cyclase effects; leaves open specificity of lipoxygenase/P450 targets in animal models.
Förstermann et al. (1988) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: